Advanced Biomed Inc. ADVB PHARMA
Company Overview
Advanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies for precision oncology detection, diagnosis, and treatment in Taiwan. Its devices include A+Pre, an automated sample preparation system that enables pre-concentration of diluted blood samples; AC-1000, a rare cell device to solve the problem of detection of hypercoagulable state samples of tumor patients; A+SCDrop, a circulating tumor cell (CTC) single-cell capture device; and A+CellScan, an analyzer with an immunostaining chip for immunostaining/analysis of the AC-1000 product. The company also offers microfluidic biochips, such as A+Pre, AC-1000 CTC enrichment, and A+CellScan chips to provide assay products and services to cancer patients. In addition, its immunochromogenic kits include A+CTCE kit to identify epithelial circulating tumor cells and determined by the immunochromogenicity of EpCAM, CK (pan), CD45, and CD14 antibodies; A+CTCM kit to identify mesenchymal circulating tumor cells based on the immunochromogenicity of Vimentin, CD45, and CD14 antibodies; A+EMT to identify epithelial-to-mesenchymal circulating tumor cells determined by the immunochromogenicity of cell-surface Vimentin, and CD45 and CD14 antibodies; and A+CM to identify tumor-associated macrophages based on the immunochromogenicity of PD-L1, CD45, and CD14 antibodies. Further, the company is developing A+LCGuard for early screening of lung cancer. Additionally, it establishes and operates medical clinics in the People's Republic of China. The company was founded in 2014 and is headquartered in New York, New York.
Why Investors Should Care
Generates a return on equity of 71.3%, reflecting efficient use of shareholder capital.
Trades at a P/E of 2.2, below the sector median of 24.8.
Carries low leverage with a debt-to-equity ratio of 0.08.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +11.69% |
| 6 Months: | +81.41% |
| 3 Months: | +127.92% |
| 1 Month: | +40.97% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)50.67 · Neutral
P/E of 2.24 is below the sector median of 24.83 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 71.3%.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 52.7% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ADVB Advanced Biomed Inc. PHARMA | 8.98 | 2.24 | $14.84M | 0.00% | -147.10% | 71.33% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2023 | Mar 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | 280.06K | 567.51K | 523.91K | 396.64K | 519.84K |
| Operating Income | - | - | - | -280.06K | -567.51K | -523.91K | -396.64K | -519.84K |
| EBITDA | - | - | - | -280.06K | -545.00K | -475.92K | -396.64K | -479.50K |
| Interest Expense | - | - | - | - | - | - | - | 112 |
| Pretax Income | - | - | - | -579.49K | -1.20M | -386.90K | 7.00M | -488.94K |
| Tax Provision | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Net Income | -145.34K | -1.06M | -265.58K | -907.90K | -1.38M | -386.90K | 6.86M | -488.94K |
| Diluted EPS | -0.01 | -0.05 | -0.01 | -0.84 | -1.35 | -0.40 | 6.20 | -0.38 |
| R&D Expense | 188.39K | 313.51K | 181.70K | 212.40K | 219.97K | 235.99K | 186.33K | 243.23K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | - |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 2.37M | 3.07M | 2.54M | - |
| Operating Income | -2.37M | -3.07M | -2.54M | - |
| EBITDA | -2.24M | -2.71M | -2.14M | - |
| Interest Expense | - | - | - | - |
| Pretax Income | -4.03M | -3.73M | -2.78M | - |
| Tax Provision | 0 | 0 | 0 | - |
| Net Income | -4.03M | -3.73M | -2.78M | - |
| Diluted EPS | -0.64 | -3.45 | -2.57 | -3.20 |
| R&D Expense | - | - | 880.19K | 909.77K |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|
| Total Assets | 6.71M | 4.60M | 4.46M | - |
| Current Assets | 5.01M | 2.79M | 3.05M | - |
| Cash & Equivalents | 4.78M | 2.62M | 2.61M | - |
| Inventory | - | - | - | - |
| Receivables | 162.52K | 149.95K | 205.18K | - |
| Total Liabilities | 3.22M | 3.29M | 2.80M | - |
| Current Liabilities | 2.99M | 3.28M | 2.73M | - |
| Long Term Debt | - | - | - | - |
| Total Debt | 468.87K | 235.37K | 126.74K | - |
| Total Equity | 3.49M | 1.31M | 1.66M | - |
| Shares Outstanding | 1.08M | 1.08M | 1.08M | 1.08M |
Cash Flows (Annual)
Figures in USD.
| Metric | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -741.45K | -2.96M | -2.13M | -5.83M |
| Investing Cash Flow | -1.08M | -263.01K | -74.11K | -31.65K |
| Financing Cash Flow | 6.10M | 458.14K | 1.87M | 5.93M |
| Capital Expenditure | -1.31M | -212.52K | -74.11K | -31.65K |
| Free Cash Flow | -2.05M | -3.18M | -2.20M | -5.86M |
| Net Change in Cash | 4.27M | -2.77M | -333.63K | - |
Ratios (Annual)
Figures in %.
| Metric | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | - | - | - | - |
| Net Margin % | - | - | - | - |
| ROE % | -115.4% | -285.9% | -167.3% | - |
| ROCE % | -63.8% | -231.9% | -147.1% | - |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Xtx Topco Ltd | 0.10% | 1.36K | $8.91K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ADVB
Advanced Biomed Inc. Announces 1 for 20 Share Consolidation
Tainan City, Taiwan, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Advanced Biomed Inc. (Nasdaq: ADVB) (the “Company” or “Advanced Biomed”), a biotechnology company focused on developing and commercializing innovative biomedical products for precision …
Advanced Biomed Inc. Announces 120‑Case Feasibility Study with Chi‑Mei Medical Center to Validate A+PerfusC™ – Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug Discovery
Tainan, Taiwan, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Advanced Biomed Inc. (Nasdaq: ADVB) (the “Company”, “Advanced Biomed”), a biotechnology company focused on developing and commercializing innovative biomedical products for precision medicin…
Advanced Biomed sells Hong Kong subsidiary for $23,000
Advanced Biomed (ADVB) entered into an agreement with an unrelated third party, Wei Ha Hui, pursuant to which the Company agreed to sell 100% of the issued and outstanding shares of Advanced Biomed Limited, a Hong Kong company and a wholly …
Advanced Biomed Inc. Announces Disposal of its Hong Kong Subsidiary
Tainan City, Taiwan, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Advanced Biomed Inc. (Nasdaq: ADVB) (the “Company”, “Advanced Biomed”), a biotechnology company focused on developing and commercializing innovative biomedical products for precision me…
Advanced Biomed Inc. Announces Launch of A+PerfusC™ – Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug Discovery
[Tainan City], Taiwan, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Advanced Biomed Inc. (Nasdaq: ADVB) (the “Company”, “Advanced Biomed”), a biotechnology company focused on developing and commercializing innovative biomedical products for precision…
ADVB — Frequently Asked Questions
What is the current share price of Advanced Biomed Inc. (ADVB)?
As of 2026-09-19 21:16 PDT, Advanced Biomed Inc. (ADVB) trades at $8.98 on NasdaqCM. Its 52-week range is $3.71 to $18.98.
What is the market capitalisation of ADVB?
Advanced Biomed Inc. (ADVB) has a market capitalisation of $14.84M on NasdaqCM.
What is the P/E ratio of ADVB?
ADVB trades at a trailing price-to-earnings (P/E) ratio of 2.24. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.28.
What is the return on equity (ROE) of ADVB?
ADVB has a return on equity (ROE) of 71.33%. Its return on capital employed (ROCE) is -147.10%.
Is ADVB a good stock to buy?
This page provides a data-driven analysis of Advanced Biomed Inc. (ADVB), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.